AWM Capital LLC Purchases 428 Shares of Johnson & Johnson (NYSE:JNJ)

AWM Capital LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 15.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,119 shares of the company’s stock after buying an additional 428 shares during the quarter. AWM Capital LLC’s holdings in Johnson & Johnson were worth $517,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson in the 4th quarter valued at $36,000. Highline Wealth Partners LLC boosted its holdings in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the period. von Borstel & Associates Inc. bought a new position in Johnson & Johnson in the 1st quarter valued at $49,000. Finally, Capital A Wealth Management LLC bought a new position in Johnson & Johnson in the 4th quarter valued at $50,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $168.29 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The firm has a market cap of $404.92 billion, a P/E ratio of 18.00, a PEG ratio of 2.14 and a beta of 0.41. The company has a 50 day moving average of $156.08 and a 200 day moving average of $155.97. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.82 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.09%. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on JNJ. Benchmark raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. UBS Group boosted their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 17th. Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $174.50.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.